EP0682656A1 - Utilisation d'urees d'heteroaryle de phenyle comme antagonistes de recepteur de 5ht 2c? et composes d'uree - Google Patents

Utilisation d'urees d'heteroaryle de phenyle comme antagonistes de recepteur de 5ht 2c? et composes d'uree

Info

Publication number
EP0682656A1
EP0682656A1 EP94905697A EP94905697A EP0682656A1 EP 0682656 A1 EP0682656 A1 EP 0682656A1 EP 94905697 A EP94905697 A EP 94905697A EP 94905697 A EP94905697 A EP 94905697A EP 0682656 A1 EP0682656 A1 EP 0682656A1
Authority
EP
European Patent Office
Prior art keywords
urea
pyridyl
quinolinyl
chloro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94905697A
Other languages
German (de)
English (en)
Inventor
Ian Thomson Smithkline Beecham Pharma. Forbes
Peter Smithkline Beecham Pharma. Ham
Roger Thomas Smithkline Beecham Pharma. Martin
Mervyn Smithkline Beecham Pharma. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0682656A1 publication Critical patent/EP0682656A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms

Definitions

  • This invention relates to a method of treatment of certain CNS disorders.
  • WO 92/05170 describes ce ⁇ ain area derivatives which are described as possessing 5HT ⁇ c receptor antagonist activity.
  • the 5HT ⁇ c receptor has recently been reclassified as the 5HT2C receptor [P. Hartig et al.. Trends in Pharmacological Sciences (TIPS) 1993].
  • 5HT2C receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimers disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • the present invention provides the use of a compound of formula (I) or a salt thereof:
  • P represents a quinoline or isoquinoline residue or a 5- or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;
  • R 1 is hydrogen, Cj.g alkyl, halogen, NR 5 R 6 or OR 7 where R 5 , R 6 and R 7 are independently hydrogen or C ⁇ _ ( - alkyl;
  • R2 and R**- * are independently hydrogen or Cj.g alkyl
  • R 4 is hydrogen, C ⁇ . ( , alkyl, CF3, nitro, cyano, acyl, halogen, NR 5 R 6 , OR 7 or CO2 7 where R--, R-- and R 7 are independently hydrogen or C ⁇ g alkyl as defined for R 1 ; and n is 1, 2 or 3, in the manufacture of a medicament for the treatment or prophylaxis of CNS disorders.
  • Cj.galkyl groups whether alone or as part of another group, can be straight chain or branched.
  • R ⁇ is hydrogen or methyl.
  • R2 and R-- are hydrogen.
  • Suitable moieties when the ring P is a 5- or 6-membered aromatic heterocyclic ring include pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, isothiazolyl, isoxazolyl, thiadiazolyl and triazolyl.
  • P is pyridyl attached to the urea nitrogen at position 3 or 4; or P is quinoline attached to the urea nitrogen at position 3, 4 or 6, preferably at position 4.
  • n is 1 or 2.
  • the R 4 groups can be the same or different.
  • the phenyl ring is mono-substituted and R 4 is CF3 or -NMe2
  • -OMe (preferably in the meta or para position); CO2Et (preferably in the meta position) or the phenyl ring is preferably di substituted with meta chloro and para methyl.
  • Preferred compounds of formula (I) include:
  • N-(3-Chloro-4-methylphenyl)-N -(3-pyridyl) urea N-(3-Chloro-4-methylphenyl)-N -(4-pyridyl) urea
  • N-(3-Pyridyl)-N'-(3-(trifluoromethyl)phenyl)urea N-(3-Methylphenyl)-N'-(3-pyridyl)urea
  • N-(4-Chlorophenyl)-N'-(3-pyridyl)urea N-(3-Chlorophenyl)-N'-(3-pyridyl)urea
  • N-(3-Hydroxyphenyl)-N'-(2-methyl-4-quinolinyl)urea N-(3-Bromophenyl)-N'-(3-pyridyl)urea, N-(3,4-Dichlorophenyl)
  • the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • Compounds of formula (I) may also form N-oxides or solvates such as hydrates, and the invention also extends to these forms.
  • Certain compounds of formula (I) may exist tautomerically in more than one form.
  • the invention extends to these and any other tautomeric forms and mixtures thereof.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
  • the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
  • Certain compounds of formula (I) are novel and form a further aspect of the invention. Particularly preferred novel compounds include those listed above and exemplified herein.
  • the invention further provides a method of treatment or prophylaxis of CNS disorders, in particular anxiety, depression, migraine, anorexia, obsessive compulsive disorders,
  • the invention also provides novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of anxiety, depression, migraine, anorexia, obsessive compulsive disorders, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse, schizophrenia and/or disorders associated with spinal trauma and/or head injuries.
  • the present invention also provides a pharmaceutical composition, which comprises novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • T e compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1 % to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months.
  • the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises
  • a and B contain the appropriate functional group(s) necessary to form the moiety, -NR2 CONR- ⁇ when coupled, the variables R - . R 2' , R 3' , and R 4 are R 1 , R 2 . R 3 , and R 4 respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any R ⁇ , R 2 , R 3 and R 4 , when other than R-, R 2 , R 3 and R 4 respectively to R-, R 2 , R 3 and R 4 , interconverting R ⁇ , R 2 . R 3 , and R 4 and forming a pharmaceutically acceptable salt thereof.
  • Suitable examples of groups A and B include:
  • A is -NR 2 COL and B is -NHR 3'
  • A is -NHR 2' and B is NR 3 COL
  • R 2 and R 3 are as defined above and L is a leaving group.
  • suitable leaving groups L include halogen such as chloro, bromo, imidazole or phenoxy or phenylthio optionally substituted for example with halogen.
  • reaction is suitably carried out in an inert solvent for example dichloromethane or toluene at ambient temperature.
  • an inert solvent for example dichloromethane or toluene at ambient temperature.
  • the reaction is suitably carried out in an inert solvent such as dichloromethane at ambient temperature optionally in the presence of a base, such as triethylamine or in dimethylformamide at ambient or elevated temperature.
  • a base such as triethylamine or in dimethylformamide at ambient or elevated temperature.
  • a is halogen and B is NR 3 CONHR 2 the reaction is suitably carried out in an inert solvent such as toluene at elevated temperature, optionally in the presence of a base.
  • Suitable examples of groups R ⁇ and R 4 which are convertible to R* and R 4 alkyl groups respectively, include acyl groups which are introduced conventionally and may be converted to the corresponding alkyl group by conventional reduction, such as using sodium borohydride in an inert solvent followed by hydrogenolysis in an inert solvent. Hydrogen substituents may be obtained from alkoxycarbonyl groups which may be converted to hydrogen by hydrolysis and decarboxylation.
  • R-, R 2 , R 3 and R 4 Interconversions of R-, R 2 , R 3 and R 4 are carried out by conventional procedures.
  • R 2 is ⁇ . alkyl and R 3 is hydrogen it is possible to introduce a C ] _6 alkyl group at the R 3 position by conventional alkylation using 1 molar equivalent of a C j .g alkyl haiide and 1 molar equivalent of a suitable base in an inert solvent.
  • Suitable examples of a group R 2 and R 3 which is convertible to R 2 and R 3 include alkoxycarbonyl and benzyl or ⁇ r ⁇ -methoxybenzyl which are converted to R 2 and R 3 is hydrogen using conventional conditions.
  • R ! halo and R 4 halo may be introduced by selective halogenation of the ring P or the benzene ring respectively using conventional conditions.
  • Compounds of formula (II) in which A is NHR 2 are known compounds or can be prepared analogously to known compounds, see, for example, WO 92/05170 (SmithKline Beecham pic).
  • A is amino, with phosgene or a phosgene equivalent, in the presence of excess base in an inert solvent.
  • A is acylazide (i.e. CON3), via the nitrene, by thermal rearrangement using conventional conditions (ref L.S. Trifonov et al, Helv. Chim. Acta 1987 7_ ⁇ 262).
  • iii) A is CONH2, via the nitrene intermediate using conventional conditions.
  • phosgene equivalents include triphosgene, carbonyldiimidazole, phenyl chloroformate and phenyl chorothioformate.
  • Compounds of formula (II) in which A is NR2'COL may be prepared by reacting a compound of formula (II) in which A is NHR2' with phosgene or a phosgene equivalent in an inert solvent, at low temperature, if necessary in the presence of one equivalent of a base such as trithylamine.
  • Compounds of formula (II) in which A is halogen and R4' is hydrogen are commercially available.
  • salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • N-oxides may be formed conventionally by reaction with hydrogen peroxide or percarboxylic acids.
  • the title compound (E4) was prepared in 56% yield from 6-aminoquinoline and phenylisocyanate following a procedure similar to that in Example 1. Free base precipitated from the reaction mixture and was recrystallised from ethanol.
  • 3-Methoxyphenyl isocyanate (0.83 ml, 6.3 mmol) in dry dichloromethane (30 ml) was added slowly to 4-aminoquinaldine (lg, 6.3 mmol) in dry toluene (30 ml) under a nitrogen atmosphere, and left to stir at room temperature for 19h.
  • the precipitate which formed was filtered off, washed with cold 1 : 1 toluene/dichloromethane and dried in vacuo.
  • the crude product was purified by recrvstallization from ethanol to give the title compound (0.99g, 51%) as a white solid, m.p. 191-193°C.
  • 3-Ethoxyc r onylphenyl isocyanate (lg, 5.2 mmol) in dry dichloromethane (30 ml), was added slowly to 4-aminoquinaldine (0.83g, 5.2 mmol) in dry toluene (30 ml), under a nitrogen atmosphere, and left to stir at room temperature for 19h.
  • the precipitate which formed was filtered off, washed with cold 1:1 toluene/dichloromethane and dried in vacuo.
  • the crude product was chromatographed on silica gel, using dichloromethane as the eluant to give the title compound (0.78g, 43%) as white crystals, m.p. 165-170°C.
  • Nicotinoyl azide (0.40g, 2.7 mmol) was stirred at reflux under nitrogen atmosphere in dry toluene (10 ml) for lh, with gas evolution. The solution was cooled to ambient temperature, and 3-chloro-4-methylaniline (0.30 ml, 2.4 mmol) was added. The suspension so formed was stirred for 1 h, when the solid was filtered off, washed with 1 : 1 toluene/dichloromethane, and dried in vacuo at 70°C. This gave the free base of the title compound (0.64g, 85%) as a white solid.
  • N-(3-Chloro-4-methyl)-N -(3-pyridyl) urea (0.55g, 2.1 mmol) was dissolved in hot ethanol (10 ml), and a solution of hydrogen chloride in ether (ca. 0.9M, 2.5 ml, ca. 2.3 mmol) was added. The suspension was cooled to ambient temperature, and the solid was filtered off, washed with cold ethanol, and dried in vacuo at 70°C. This gave the title compound (0.62g, 76%) as a white solid, m.p. 214.5-216°C.
  • 3-Chloro-4-methvlaniline (0.65 ml, 5.3 mmol) was stirred under nitro ⁇ en in dichloromethane ( 15 ml) at 0°C as triethylamine (0.82 ml, 5.9 mmol) was added. To this mixture was then added phosgene in toluene solution (1.93M, 4.1 ml, 7.9 mmol). After stirring at 0°C for 0.5h, triethylamine (1.6 ml, 1 1.8 mmol) was added and, after a further 0.5h, 4-aminopyridine (0.50g, 5.3 mmol) w*_s added.
  • N-(3-Chloro-4-methylphenyl)-N -(4-pyridyl) urea (1.03g, 3.9 mmol) was treated with hydrogen chloride using the method of Example 11. This gave the title compound (0.95g, 81 %) as a white solid, m.p. 235-240°C (decomp.).
  • the title compound was prepared in 91% yield from 3-pyridyl isocyanate and 3- aminobenzotrifluoride; m.p. 180-184° C.
  • the title compound was prepared in 87% yield from 3-aminopyridine and m-tolyl isocyanate, followed by salt formation with HC1; m.p. 182-183° C.
  • the title compound was prepared in 29% yield from 3-aminopyridine, 1,1'- carbonyldiimidazole and 4-chloroaniline; m.p. 207-209° C
  • the title compound was prepared in 75% yield from 3-bromopyridine and 3-pyridyl isocyanate: m.p. 190-193° C.
  • the title compound was prepared in 65% yield from 3,4-dichloroaniline and 3-pyridyl isocyanate; m.p. 206° C-210° C.
  • the title compound was prepared in 85% yield from 3-fluoro-4-methylaniline and 3- pyridyl isocyanate; m.p. 190-191 ° C.
  • the title compound was prepared in 73% yield from 3-chloro-4-tert-butylaniline & 3- pyridyl isocyanate; m.p. 190° C-193 0 C.
  • N-(3-Hydroxy-4-carboxyphenyl)-N'-(3-pyridyl)urea was prepared in 69% yield from 4- aminosalicylic acid and 3-pyridyl isocyanate in DMF/toluene. This material (0.37g, 1.4 mmol) was then stirred in methanol (20 ml) as thionyl chloride (2 ml) was cautiously added. The suspension was stirred at reflux under argon for 2 days, and evaporated to dryness. The residue was suspended in saturated sodium hydrogen carbonate solution, and the solid was filtered off, washed with water, dried, and recrystallised from ethanol/petroleum ether (b.p. 60-80° C), giving the title compound (0.16g, 41%) as a white solid, m.p. 199-200° C. NMR (DMSO d ⁇ ) ⁇ :
  • 5-HT? antagonists may have a number of therapeutic indications including the treatment f anxiety, migraine, depression, feeding disorders and obsessive compulsion disorders. (Curzon and Kennett, 1990; Fozard and Gray, 1989) and Alzheimer's Disease (Lawlor, 1989, J. Arch. Gen. Psychiat. Vol. 46 p.542).
  • the affinity of test drugs for the 5-HT2C binding site can be determined by assessing their ability to displace [ 3 H]-mesulergine from 5-HT2 clones expressed in 293 cells (Julius et al., 1988). The method employed was similar to that of Pazos et al, 1984.
  • the cells suspension (50ml) was incubated with [ 3 H]-mesulergine (0.5nM) in Tris HC1 buffer (pH 7.4) at 37°C for 30 minutes. Non-specific binding was measured in the presence of mianserin (10""M). Ten concentrations of test drug (3 x 10"9 to 10 " M final concentration) were added in a volume of 50ml. The total assay volume was 500ml. Incubation was stopped by rapid filtration using a Brandel cell harvester and radioactivity measured by scintillation counting. The IC50 values were determined using a four parameter logistic program O eLean 1978) and the pKj (the negative logarithm of the inhibition constant) calculated from the Cheng Prusoff equation where:
  • Kd Affinity of mesulergine for 5-HT-J C binding sites.
  • the compound of Example 7 has a pKi of 8.28.
  • the compound of Example 11 has a pKi of 7.79.
  • mCPP-induced hypolocomotion was measured in automated locomotion cages of dimensions 56 cm long x 1614 cm wide x 25 cm high and made of black perspex. Two photobeams traversed the width of the cages at either end at ground level. Sequential breaking of these beams allowed the measurement of cage transits.
  • mice Male Sprague Dawley rats (200-250g) (Charles River) were housed in groups of six. They were given drugs orally lh pretest and 40 mins later mCPP (7 mg/kg i.p.). After a further 20 min they were placed in individual automated cages in groups of four under red light in an adjacent room. After 10 min the test was terminated. Reversal of mCPP-induced hypolocomotion was considered as evidence of in vivo central 5-HT2C receptor antagonist properties.
  • the compound of Example 11 had an ID50 of 78 mg/kg p.o.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Utilisation d'un composé de la formule (1) ou d'un sel de ce composé, formule dans laquelle P représente un reste de quinoline ou d'isoquinoline ou un noyau hétérocyclique aromatique à 5 ou 6 éléments contenant jusqu'à trois hétéroatomes choisis entre azote, oxygène et soufre; R1 représente hydrogène, alkyle C¿1-6?, halogène, NR?5R6 ou OR7, R5, R6 et R7¿ représentant indépendamment hydrogène ou alkyle C¿1-6; R?4 représente hydrogène, alkyle C¿1-6?, CF3, nitro, cyano, acyle, halogène, NR?5R6, OR7¿ ou CO¿2?R?7, R5, R6 et R7¿ représentant indépendamment hydrogène ou alkyle C¿1-6? tels que définis pour R?1¿; et n vaut 1, 2 ou 3. Ce composé ou son sel peuvent être utilisés pour la préparation d'un médicament destiné au traitement ou à la prophylaxie de troubles du système nerveux central.
EP94905697A 1993-02-05 1994-01-25 Utilisation d'urees d'heteroaryle de phenyle comme antagonistes de recepteur de 5ht 2c? et composes d'uree Withdrawn EP0682656A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939302275A GB9302275D0 (en) 1993-02-05 1993-02-05 Novel compounds
GB9302275 1993-02-05
PCT/EP1994/000189 WO1994018170A1 (fr) 1993-02-05 1994-01-25 Utilisation d'urees d'heteroaryle de phenyle comme antagonistes de recepteur de 5ht2c et composes d'uree

Publications (1)

Publication Number Publication Date
EP0682656A1 true EP0682656A1 (fr) 1995-11-22

Family

ID=10729906

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94905697A Withdrawn EP0682656A1 (fr) 1993-02-05 1994-01-25 Utilisation d'urees d'heteroaryle de phenyle comme antagonistes de recepteur de 5ht 2c? et composes d'uree

Country Status (4)

Country Link
EP (1) EP0682656A1 (fr)
JP (1) JPH08506114A (fr)
GB (1) GB9302275D0 (fr)
WO (1) WO1994018170A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080763A (en) 1997-11-03 2000-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds and their use as anti-inflammatory agents
EP1473292A1 (fr) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Composes heterocycliques aromatiques convenant en tant qu'agents anti-inflammatoires
WO1999032455A1 (fr) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition de raf kinase a l'aide d'urees heterocycliques aryle et heteroaryle substituees
WO2000035455A1 (fr) 1998-12-15 2000-06-22 Telik, Inc. Urees heteroaryle-aryle utilisees comme antagonistes du recepteur igf-1
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (fr) 1999-01-13 2011-12-28 Bayer HealthCare LLC DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE60013250T2 (de) * 1999-02-12 2005-09-08 Smithkline Beecham P.L.C., Brentford Phenylharnstoff- und Phenylthioharnstoffderivate als Orexinrezeptorantagonisten
AU2910600A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives
JP2002537397A (ja) 1999-02-22 2002-11-05 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての多環ヘテロ環式誘導体
IL144897A0 (en) 1999-03-12 2002-06-30 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
MXPA01009077A (es) 1999-03-12 2002-03-27 Boehringer Ingelheim Pharma Composiciones heterociclicos aromaticos como agentes anti-inflamatorios.
JP4162406B2 (ja) 1999-07-09 2008-10-08 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ヘテロアリール置換ウレア化合物の新規合成方法
DE60036726T2 (de) 1999-11-16 2008-02-07 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Harnstoff derivate als entzündungshemmende mittel
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
JP4366936B2 (ja) * 2001-04-20 2009-11-18 バイエル コーポレイション キノリル、イソキノリルまたはピリジル尿素を使用するｒａｆキナーゼの阻害
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
EP1395561A1 (fr) 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Composes de carbamate et d'oxamide inhibant la production de cytokine
ES2425739T3 (es) 2002-02-11 2013-10-17 Bayer Healthcare Llc Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal
DK1580188T3 (da) 2002-02-11 2012-02-06 Bayer Healthcare Llc Forbindelser af arylurea som kinaseinhibitorer
ATE386030T1 (de) 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
PL1636585T3 (pl) 2003-05-20 2008-10-31 Bayer Healthcare Llc Diarylowe pochodne mocznika inhibowane kinazą
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
WO2008084043A1 (fr) 2007-01-09 2008-07-17 Novo Nordisk A/S Activateurs de la glucokinase à base d'urée
WO2009035951A2 (fr) * 2007-09-11 2009-03-19 Arete Therapeutics, Inc. Inhibiteurs d'époxyde hydrolase soluble
CN109645019B (zh) * 2017-10-11 2021-12-24 中国疾病预防控制中心寄生虫病预防控制所 具有杀螺活性的吡啶脲类化合物的用途
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
CN114600893A (zh) * 2022-04-15 2022-06-10 江西省农业科学院植物保护研究所 一种吡螺脲漂浮粒剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880817A (en) * 1987-06-09 1989-11-14 Ortho Pharmaceutical Corporation O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
CA2076012A1 (fr) * 1990-02-14 1991-08-15 Yasuyuki Kato Agent inhibiteur de la formation de ldl denatures
US5328922A (en) * 1990-09-13 1994-07-12 Beecham Group P.L.C. Indole ureas as 5 ht receptor antagonist
JPH04173701A (ja) * 1990-11-06 1992-06-22 Hokko Chem Ind Co Ltd 水稲用除草剤のための薬害軽減剤
AU659861B2 (en) * 1991-09-10 1995-06-01 Sansho Seiyaku Co., Ltd. Preparation for promoting hair growth
EP0630373A1 (fr) * 1992-03-12 1994-12-28 Smithkline Beecham Plc Derives d'indole utilises comme antagonistes de 5ht 1c?

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9418170A1 *

Also Published As

Publication number Publication date
WO1994018170A1 (fr) 1994-08-18
JPH08506114A (ja) 1996-07-02
GB9302275D0 (en) 1993-03-24

Similar Documents

Publication Publication Date Title
EP0682656A1 (fr) Utilisation d'urees d'heteroaryle de phenyle comme antagonistes de recepteur de 5ht 2c? et composes d'uree
US5508288A (en) Indole derivatives as 5HT1C antagonists
CA2559733C (fr) Inhibiteurs d'histone desacetylase
JP3095521B2 (ja) ピペラジン誘導体
WO1994014801A1 (fr) Derives heterocycliques de l'uree antagonistes de 5ht2c et 5h¿2b?
DE60222396T2 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
AU779034B2 (en) Benzanilides as potassium channel openers
KR100360633B1 (ko) Ｎｏｓ 억제제로서 유용한 6-페닐피리딜-2-아민 유도체
US20050026964A1 (en) 5-Substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives
US5866586A (en) CNS-active pyridinylurea derivatives
JP2001526643A (ja) ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つ化合物を含む二環式アリールまたは二環式複素環
WO1997008167A1 (fr) Antagonistes des recepteurs 5ht2c et 5ht¿2b?
JPH04273870A (ja) ２−アミノピリミジン−４−カルボキサミド誘導体、その製造と医療における使用
CA2299286A1 (fr) Composes bicycliques servant de ligands pour les recepteurs 5-ht1
US5135931A (en) Pyridinylpiperazine derivatives
WO1994022871A1 (fr) DERIVES THIENO-INDOLIQUES UTILISES COMME ANTAGONISTES DE 5HT2c ET DE 5HT2b
US6313145B1 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
US6369060B1 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
WO1997011054A1 (fr) Composes d'acide benzoique et leur emploi medical
US6031097A (en) 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
WO1997032854A1 (fr) Derives de 2-sulfinylnicotinamide, intermediaire de ces derives, procede pour produire ces derives et composition medicinale contenant ces derives comme ingredient actif
JPH0741481A (ja) 両性型三環系化合物
CA2293480A1 (fr) 2-aminoalkylaminoquinoleines utilisees comme ligands de la dopamine d4
RU2211216C2 (ru) Производные амидов и мочевины в качестве ингибиторов вторичного поглощения 5-ht и лигандов 5-ht1b/1d
MXPA99010869A (en) 2-aminoalkylaminoquinolines as dopamine d4

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950725

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

17Q First examination report despatched

Effective date: 19960619

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19961030